Literature DB >> 28461648

An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group.

Monika E Finger1,2, Annelies Boonen1,2, Thasia G Woodworth1,2, Reuben Escorpizo1,2, Robin Christensen1,2, Sabrina M Nielsen1,2, Amye L Leong1,2, Marieke Scholte Voshaar1,2, Caroline A Flurey1,2, Nataliya Milman1,2, Suzanne M Verstappen1,2, Rieke Alten1,2, Francis Guillemin1,2, Margreet Kloppenburg1,2, Dorcas E Beaton1,2, Peter S Tugwell1,2, Lyn M March1,2, Daniel E Furst1,2, Christoph Pohl3,4.   

Abstract

OBJECTIVE: The importance of contextual factors (CF) for appropriate patient-specific care is widely acknowledged. However, evidence in clinical trials on how CF influence outcomes remains sparse. The 2014 Outcome Measures in Rheumatology (OMERACT) Handbook introduced the role of CF in outcome assessment and defined them as "potential confounders and/or effect modifiers of outcomes in randomized controlled trials." Subsequently, the CF Methods Group (CFMG) was formed to develop guidance on how to address CF in clinical trials.
METHODS: First, the CFMG conducted an e-mail survey of OMERACT working groups (WG) to analyze how they had addressed CF in outcome measurement so far. The results facilitated an informed discussion at the OMERACT 2016 CFMG Special Interest Group (SIG) session, with the aim of gaining preliminary consensus regarding an operational definition of CF and to make a first selection of potentially relevant CF.
RESULTS: The survey revealed that the WG had mostly used the OMERACT Handbook and/or the International Classification of Functioning, Disability and Health (ICF) definition. However, significant heterogeneity was found in the methods used to identify, refine, and categorize CF candidates. The SIG participants agreed on using the ICF as a framework along with the OMERACT Handbook definition. A list with 28 variables was collected including person-related factors and physical and social environments. Recommendations from the SIG guided the CFMG to formulate 3 preliminary projects on how to identify and analyze CF.
CONCLUSION: New methods are urgently needed to assist researchers to identify and characterize CF that significantly influence the interpretation of results in clinical trials. The CFMG defined first steps to develop further guidance.

Entities:  

Keywords:  CONTEXTUAL; EFFECT MODIFIER; OMERACT; PATIENT-REPORTED OUTCOMES; RANDOMIZED CONTROLLED TRIALS; RHEUMATOLOGY

Mesh:

Year:  2017        PMID: 28461648     DOI: 10.3899/jrheum.161200

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  2 in total

Review 1.  The Application of Preference Elicitation Methods in Clinical Trial Design to Quantify Trade-Offs: A Scoping Review.

Authors:  Megan Thomas; Deborah A Marshall; Daksh Choudhary; Susan J Bartlett; Adalberto Loyola Sanchez; Glen S Hazlewood
Journal:  Patient       Date:  2021-12-20       Impact factor: 3.481

2.  Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health.

Authors:  Nataliya Milman; Eilish McConville; Joanna C Robson; Annelies Boonen; Peter Tugwell; George A Wells; Dipayan Chaudhuri; Jill Dawson; Gunnar Tomasson; Susan Ashdown; Don Gebhart; Georgia Lanier; Jacqueline Peck; Carol A McAlear; Katherine S Kellom; Peter F Cronholm; Peter A Merkel
Journal:  J Rheumatol       Date:  2019-02-01       Impact factor: 4.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.